Topical finasteride is sold on a single, very appealing idea: get the DHT blocking where you need it, on the scalp, without flooding the rest of your body with the drug. Keep the regrowth, lose the side effect risk.

The first half of that promise has real trial data behind it. The second half is where things get complicated — and where, in April 2025, the FDA stepped in with a warning that most marketing pages still do not mention.

The trial that made the case

Most hair loss products are backed by a small open-label study and a lot of before-and-after photos. Topical finasteride is an exception: a standardized 0.25% spray solution went through a full phase III program.

That is a genuinely strong result for a topical. Roughly three times the hair count gain of placebo, in a properly blinded trial, with an effect size in the same neighbourhood as the pill. A standardized version of this spray has since been approved and marketed in several countries outside the United States.

Two caveats worth holding onto. Twenty-four weeks is short for hair loss — the oral finasteride trials that established its reputation ran for one to two years, and the gap between drug and placebo widens over time mostly because the placebo group keeps losing. And “numerically similar to oral” is not the same as “proven equivalent to oral.” The trial was not designed to prove non-inferiority.

The DHT numbers are the whole argument

The reason anyone bothers with a topical version comes down to pharmacokinetics.

This is the mechanism the entire category rests on. If scalp DHT is what drives follicle miniaturization, and you can suppress scalp DHT while leaving most of your circulating DHT intact, you should in principle keep the benefit and shrink the risk.

The logic is sound. The word doing the heavy lifting is “shrink.”

Topical does not mean it stays on your scalp

A 27% drop in serum DHT is not zero. It is roughly 40% of the systemic effect of the pill, delivered to your bloodstream, every day.

This matters because the sexual and neuropsychiatric side effects people worry about with finasteride are systemic effects — they are not happening in your scalp. Reducing systemic exposure should reduce their likelihood. It does not eliminate the pathway. Anyone telling you a topical carries “no risk because it’s topical” is either misinformed or selling something.

Absorption also varies a lot with formulation. The trial product used a specific hydroxypropyl chitosan vehicle designed to hold the drug in the skin. Alcohol and propylene glycol vehicles, which most compounding pharmacies use, behave differently and are generally thought to push more drug through into circulation.

What the FDA actually said

In April 2025, the FDA issued an alert to prescribers, compounding pharmacies, and consumers about compounded topical finasteride products.

The agency described 32 adverse event reports submitted between 2019 and 2024 involving compounded topical finasteride, alone or combined with other actives. Reported symptoms included erectile dysfunction, decreased libido, testicular pain, anxiety, depression, brain fog, fatigue, insomnia, and suicidal ideation — the same profile associated with the oral drug. Most reports stated the symptoms continued after the product was stopped.

Two details from the alert are worth repeating. Some consumers said they had not been told there were any risks at all. Some said a prescriber had told them there was no risk specifically because the product was topical.

Thirty-two spontaneous reports over six years is not an incidence rate, and it cannot tell you how likely any of this is. Spontaneous reporting systems capture a small and unrepresentative fraction of what happens. But the alert makes a point that stands on its own: these compounded products have not been evaluated by the FDA for safety or effectiveness, and the “topical means safe” framing is not supported.

The counterweight from the randomized data

The controlled evidence looks more reassuring than the report tally.

So which do you believe? Both, honestly. Randomized trials are the better tool for estimating how common something is, and they suggest topical finasteride is well tolerated for most men over the studied timeframes. Trials are also short, enroll selected participants, and are underpowered to detect uncommon events. Pharmacovigilance reports are the better tool for spotting rare or delayed problems, and they are terrible at telling you how often those problems occur.

The reasonable read: the risk is real but appears lower than with oral finasteride, and it is not zero.

Compounded is not the product that was studied

This is the gap that trips people up most.

The trials above tested one specific 0.25% spray with a defined vehicle, a defined dose, and a defined application method. What most people in the US actually receive is a compounded preparation from a telehealth service or pharmacy, often at a different concentration, often blended with minoxidil, in a vehicle chosen by the compounder.

Those products are legal under Section 503A when made against a valid patient-specific prescription. They are not FDA-approved, and their concentration, absorption, and stability were not the ones in the trial. Efficacy data from the spray does not automatically transfer, and neither does the safety data.

If you go this route, ask the prescriber directly: what concentration, what vehicle, is the compounder a 503A or 503B facility, and what potency testing is done.

The minoxidil combination question

Most compounded topical finasteride is sold blended with minoxidil, and there is a reasonable rationale for pairing them: they work through unrelated mechanisms, so combining them is additive rather than redundant.

Chandrashekar and colleagues (2015, Indian Dermatology Online Journal) followed 50 men who had been on topical minoxidil plus oral finasteride for two years and then swapped the pill for a 5% minoxidil solution fortified with 0.1% finasteride. Of the 45 who continued treatment, about 84% maintained good hair density on the topical combination. It is a small, open-label maintenance study rather than a regrowth trial, but it is the study most often cited for the combination approach. More recent systematic reviews pooling randomized trials of minoxidil-finasteride combination solutions have also favoured the combination over minoxidil alone on hair density measures.

Worth noting: nothing stops you running the two separately. Minoxidil is over the counter, well studied, and the piece of the stack you can start today without a prescription.

If you are managing flaking or seborrheic dermatitis alongside a topical routine, ketoconazole shampoo is a cheap and reasonably well-supported add-on.

Who should not use it

Finasteride in any form is not appropriate for women who are pregnant, may become pregnant, or are breastfeeding — it can cause genital malformations in a male fetus. This is not a theoretical concern with topicals: transfer from treated skin is possible, and partners and children should not come into contact with a freshly applied product.

Some dermatologists do prescribe topical finasteride off-label to postmenopausal women, but that is a conversation for a specialist, not something to try on your own.

Also skip it, or get proper advice first, if you have liver disease, are being monitored for prostate cancer (finasteride lowers PSA and complicates interpretation), or have a history of depression.

What to actually do with this

If you are already on oral finasteride and tolerating it well, there is no strong reason to switch. The oral drug has decades of data and the longest efficacy record.

If side effects are what is keeping you off finasteride entirely, topical is a legitimate option to raise with a doctor — with the honest framing that it lowers systemic exposure substantially rather than removing it.

If you are choosing topical because someone told you it was risk-free, choose again on better information.

And whichever way you go, give it time and track it properly. Photos at week zero, then monthly, same lighting, same angle, same hair length. Judge at six months, not six weeks.

Topical finasteride is prescription-only in the United States and requires a doctor’s involvement. This article is for informational purposes only and is not medical advice. Talk to a healthcare provider before starting or stopping any treatment.